<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146093</url>
  </required_header>
  <id_info>
    <org_study_id>AAI-US-138</org_study_id>
    <nct_id>NCT01146093</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fed Conditions</brief_title>
  <official_title>Single Dose Two-Way Crossover Fed Bioequivalence Study of Pravastatin 80 mg Tablets in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single Dose Two-Way Crossover Fed Bioequivalence Study of Pravastatin 80 mg Tablets
      of Dr.Reddy's Laboratories Limited with Pravachol 80mg, Bristol Myers Squibb in Healthy
      Volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single Dose Two-Way Crossover Fed Bioequivalence Study of Pravastatin 80 mg Tablets of
      Dr.Reddy's Laboratories Limited with Pravachol 80 mg, Bristol Myers Squibb in Healthy
      Volunteers.

      A total of 24 non-smoking subjects (18 men and 6 women) were included in this study, of which
      23 finished the study according to the protocol.

      The washout period (7 days) between the two periods of the study and with an equal number of
      subjects randomly assigned
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">November 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Pravastatin Sodium Tablets 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dr.Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravachol 80 mg Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bristol Myers Squibb</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin Sodium</intervention_name>
    <description>Pravastatin Sodium Tablets 80 mg</description>
    <arm_group_label>Pravastatin Sodium Tablets 80 mg</arm_group_label>
    <arm_group_label>Pravachol 80 mg Tablets</arm_group_label>
    <other_name>Pravachol 80 mg tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females at least 18 years of age inclusive.

          -  Informed of the nature of the study and given written informed consent.

          -  Have a body weight within 15% of the appropriate range as defined in the 1983
             Metropolitan Life Company tables and weighing at least 100 lbs. (Appendix I and II).

        Exclusion Criteria:

          -  Hypersensitivity to Pravastatin (pravacholÂ®), or similar compounds.

          -  Any history of a clinical condition which might affect drug absorption, metabolism or
             excretion.

          -  Recent history (within 1 year) of mental illness, drug addiction, drug abuse or
             alcoholism.

          -  Donation of greater than 500 m1 of blood in the past 4 weeks prior to study dosing or
             difficulty in donating blood.

          -  Received an investigational drug within the 4 weeks prior to study dosing.

          -  Currently taking any prescription medication, except oral contraceptives, within the 7
             days prior to study dosing or over-the-counter medication within 3 days of study
             dosing. This prohibition does not include vitamins, or herbal preparations taken as
             nutritional supplements for non-therapeutic indications as judged by the attending
             physician.

          -  Tobacco use (&gt;5 cigarettes per day) in the 3 months prior to study dosing.

          -  If female, the subject is lactating or has a positive pregnancy test at screening and
             prior to each of the two treatment periods. Females of child bearing potential must
             use a medically acceptable method of contraception throughout the entire study period
             and for one week after the study is completed. Medically acceptable methods of
             contraception that may be used by the subject and/or her partner are: oral
             contraceptives, progestin injection or implants, condom with spermicide, diaphragm
             with spermicide, IUD, vaginal spermicidal suppository, surgical sterilization of their
             partner(s) or abstinence. Females taking oral contraceptives must have taken them
             consistently for at least three months prior to receiving study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Scallion EE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AAI, 6101 Quadrangle Drive, Chapel Hill, NC 27514</affiliation>
  </overall_official>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2010</study_first_posted>
  <last_update_submitted>January 12, 2012</last_update_submitted>
  <last_update_submitted_qc>January 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2012</last_update_posted>
  <responsible_party>
    <name_title>Director</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

